Crgd-Zw800-1
Pancreas Adenocarcinoma
Leiden University Medical CenterPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
189 Active assets in the Pancreas Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Jonsson Comprehensive Cancer Center | Phase 4 | BBB |
Docetaxel Bristol-Myers Squibb | Phase 2 | BBB |
Irinotecan Jonsson Comprehensive Cancer Center | Phase 3 | BB |
Eloxatin Jonsson Comprehensive Cancer Center | Phase 4 | BB |
Irinotecan Ipsen | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Crgd-Zw800-1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →